🟢 Arcturus Therapeutics is trading 5.3% up today amid optimism over returned rights and reduced liabilities

Arcturus Therapeutics is trading 5.3% up at $10.82, with the move appearing to extend investor enthusiasm over the CSL collaboration termination.

• On August 19, shares rose 25.21%; the termination returned global KOSTAIVE and vaccine rights, provided $12 million in cash, and eliminated approximately $16 million in R&D liabilities.
• Canaccord maintained a Buy rating while reducing its target to $20 from $21.
• The broader biotech sector is weaker, so company-specific optimism, supported by Arcturus’s cash position and clinical pipeline progress, remains the stronger explanation.